KEAP1 and cancer: CDDO-Me is more potent than CDDO in terms of its anticancer and cancer-preventive activities and ability to activate the Keap1/Nrf2/ARE pathway, which is involved in oxidative stress [14, 24], and the anti-SARS-CoV-2 activity of CDDO-Me has a greater inhibitory effect on SARS-CoV-2 replication than that of CDDO [47].